Plasma epstein-barr virus DNA concentration and clearance rate as novel prognostic factors for metastatic nasopharyngeal carcinoma

Head and Neck

Volumn 34, Issue 8, 2012, Pages 1064-1070

  Hsu, Cheng Lung ^a   Chang, Kai Ping ^a   Lin, Chien Yu ^a   Chang, Hsien Kun ^a   Wang, Cheng Hsu ^a   Lin, Tung Liang ^a   Liao, Chun Ta ^a   Tsang, Ngan Ming ^a   Lee, Li Yu ^a   Chan, Sheng Chieh ^a   Ng, Shu Hang ^a   Li, Hsin Pai ^a   Chang, Yu Sun ^a   Wang, Hung Ming ^a  

^a CHANG GUNG UNIVERSITY   (Taiwan)

Author keywords

chemotherapy; DNA; epstein barr virus; head and neck cancer; nasopharyngeal cancer

Indexed keywords

CISPLATIN; FOLINATE CALCIUM; GEMCITABINE; UFT; VIRUS DNA;

ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER SURVIVAL; DISEASE FREE INTERVAL; DISTANT METASTASIS; EPSTEIN BARR VIRUS; FEMALE; GENE DOSAGE; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; METASTASIS; NASOPHARYNX CARCINOMA; OVERALL SURVIVAL; PLASMA CLEARANCE; PLASMA HALF LIFE; PRIORITY JOURNAL; PROSPECTIVE STUDY; REAL TIME POLYMERASE CHAIN REACTION; SURVIVAL PREDICTION; TREATMENT OUTCOME; TREATMENT RESPONSE; VIRAL CLEARANCE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA; DNA, VIRAL; FEMALE; HALF-LIFE; HERPESVIRUS 4, HUMAN; HUMANS; MALE; MIDDLE AGED; NASOPHARYNGEAL NEOPLASMS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; REAL-TIME POLYMERASE CHAIN REACTION;

EID: 84864278288     PISSN: 10433074     EISSN: 10970347     Source Type: Journal    
DOI: 10.1002/hed.21890     Document Type: Article

References (27)

1. Al-Sarraf M, LeBlanc M, Giri PG, et al. Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099. J Clin Oncol 1998; 16: 1310-1317.
2. Lin JC, Jan JS, Chen KY, Hsu CY, Liang WM, Wang WY,. Outpatient weekly 24-hour infusional adjuvant chemotherapy of cisplatin, 5-fluorouracil, and leucovorin for high-risk nasopharyngeal carcinoma. Head Neck 2003; 25: 438-450.
3. Lin JC, Jan JS, Hsu CY, Liang WM, Jiang RS, Wang WY,. Phase III study of concurrent chemoradiotherapy versus radiotherapy alone for advanced nasopharyngeal carcinoma: positive effect on overall and progression-free survival. J Clin Oncol 2003; 21: 631-637.
4. Teo PM, Kwan WH, Chan AT, Lee WY, King WW, Mok CO,. How successful is high-dose (>or = 60 Gy) reirradiation using mainly external beams in salvaging local failures of nasopharyngeal carcinoma? Int J Radiat Oncol Biol Phys 1998; 40: 897-913.
5. Leung TW, Tung SY, Sze WK, et al. Salvage radiation therapy for locally recurrent nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys 2000; 48: 1331-1338.
6. Chang JT, See LC, Liao CT, et al. Locally recurrent nasopharyngeal carcinoma. Radiother Oncol 2000; 54: 135-142.
7. Lo YM, Chan LY, Lo KW, et al. Quantitative analysis of cell-free Epstein-Barr virus DNA in plasma of patients with nasopharyngeal carcinoma. Cancer Res 1999; 59: 1188-1891.
8. Lo YM, Leung SF, Chan LY, et al. Kinetics of plasma Epstein-Barr virus DNA during radiation therapy for nasopharyngeal carcinoma. Cancer Res 2000; 60: 2351-2355.
9. Lo YM, Chan LY, Chan AT, et al. Quantitative and temporal correlation between circulating cell-free Epstein-Barr virus DNA and tumor recurrence in nasopharyngeal carcinoma. Cancer Res 1999; 59: 5452-5455.
10. Lo YM, Chan AT, Chan LY, et al. Molecular prognostication of nasopharyngeal carcinoma by quantitative analysis of circulating Epstein-Barr virus DNA. Cancer Res 2000; 60: 6878-6881.
11. Lin JC, Wang WY, Chen KY, et al. Quantification of plasma Epstein-Barr virus DNA in patients with advanced nasopharyngeal carcinoma. N Engl J Med 2004; 350: 2461-2470.
12. Mutirangura A, Pornthanakasem W, Theamboonlers A, et al. Epstein-Barr viral DNA in serum of patients with nasopharyngeal carcinoma. Clin Cancer Res 1998; 4: 665-669.
13. Leung SF, Zee B, Ma BB, et al. Plasma Epstein-Barr viral deoxyribonucleic acid quantitation complements tumor-node-metastasis staging prognostication in nasopharyngeal carcinoma. J Clin Oncol 2006; 24: 5414-5418.
14. To EW, Chan KC, Leung SF, et al. Rapid clearance of plasma Epstein-Barr virus DNA after surgical treatment of nasopharyngeal carcinoma. Clin Cancer Res 2003; 9: 3254-3259.
15. Wang WY, Twu CW, Chen HH, et al. Plasma EBV DNA clearance rate as a novel prognostic marker for metastatic/recurrent nasopharyngeal carcinoma. Clin Cancer Res 2010; 16: 1016-1024.
16. Sozzi G, Conte D, Leon M, et al. Quantification of free circulating DNA as a diagnostic marker in lung cancer. J Clin Oncol 2003; 21: 3902-3908.
17. Kwong D, Sham J, Choy D,. The effect of loco-regional control on distant metastatic dissemination in carcinoma of the nasopharynx: an analysis of 1301 patients. Int J Radiat Oncol Biol Phys 1994; 30: 1029-1036.
18. Geara FB, Sanguineti G, Tucker SL, et al. Carcinoma of the nasopharynx treated by radiotherapy alone: determinants of distant metastasis and survival. Radiother Oncol 1997; 43: 53-61.
19. Teo PM, Kwan WH, Lee WY, Leung SF, Johnson PJ,. Prognosticators determining survival subsequent to distant metastasis from nasopharyngeal carcinoma. Cancer 1996; 77: 2423-2431.
20. Toh CK, Heng D, Ong YK, Leong SS, Wee J, Tan EH,. Validation of a new prognostic index score for disseminated nasopharyngeal carcinoma. Br J Cancer 2005; 92: 1382-1387.
21. Khanfir A, Frikha M, Ghorbel A, Drira MM, Daoud J,. Prognostic factors in metastatic nasopharyngeal carcinoma. Cancer Radiother 2007; 11: 461-464.
22. Ng SH, Chan SC, Yen TC, et al. Staging of untreated nasopharyngeal carcinoma with PET/CT: comparison with conventional imaging work-up. Eur J Nucl Med Mol Imaging 2009; 36: 12-22.
23. Chang JT, Chan SC, Yen TC, et al. Nasopharyngeal carcinoma staging by (18)F-fluorodeoxyglucose positron emission tomography. Int J Radiat Oncol Biol Phys 2005; 62: 501-507.
24. Ngan RK, Lau WH, Yip TT, et al. Remarkable application of serum EBV EBER-1 in monitoring response of nasopharyngeal cancer patients to salvage chemotherapy. Ann N Y Acad Sci 2001; 945: 73-79.
25. Foo KF, Tan EH, Leong SS, et al. Gemcitabine in metastatic nasopharyngeal carcinoma of the undifferentiated type. Ann Oncol 2002; 13: 150-156.
26. Ngan RK, Yiu HH, Lau WH, et al. Combination gemcitabine and cisplatin chemotherapy for metastatic or recurrent nasopharyngeal carcinoma: report of a phase II study. Ann Oncol 2002; 13: 1252-1258.
27. Wang J, Li J, Hong X, et al. Retrospective case series of gemcitabine plus cisplatin in the treatment of recurrent and metastatic nasopharyngeal carcinoma. Oral Oncol 2008; 44: 464-470.